Philip Morris InternationalPM
PM logo
Fair Value
US$203.8
Share price20 Aug
US$188.237.6% undervalued intrinsic discount
Loading
1Y9.60%
7D-1.13%

PM: Share Pullback Will Present Attractive Buying Opportunity Following Guidance Update

Analyst Consensus Target compiles analysts opinions to create narratives on stocks using the Analysts Consensus Price Target, forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published
16 Jul 24
Updated
20 Aug 26
Views
1.2k
Not Invested

Last Update 20 Aug 26

Fair value Increased 5.52%

PM: Smoke Free Shift And FDA Rulings Will Shape Balanced Risk Profile

Analysts have raised their average price target for Philip Morris International to about $204 from about $193, citing recent research that highlights confidence in IQOS and pouch volumes, a resilient combustible business, and modestly higher margin and P/E assumptions despite slightly softer modeled revenue growth.

Analyst Commentary

Recent Street commentary around Philip Morris International focuses on how the company is executing on reduced risk products, the resilience of its combustible portfolio, and what that could mean for valuation and medium term growth expectations.

Bullish Takeaways

  • Bullish analysts see the IQOS and pouch businesses as key pillars for Philip Morris International, with several targeting higher valuations based on confidence in these categories and the view that 2026 IQOS headwinds are temporary.
  • Some highlight recent Q2 earnings and describe continued strength in the combustible business and improving sentiment on US pouches and broader heated products, which they view as supportive of earnings and P/E assumptions.
  • Certain firms point to the company’s execution in shifting toward reduced risk products while keeping combustibles resilient. They argue that this mix supports a premium valuation versus peers.
  • There is also commentary that ZYN regaining some lost share and new launches such as ZYN Ultra in the US could help Philip Morris International return to a more consistent pattern of meeting or exceeding earnings expectations over time.

Bearish Takeaways

  • More cautious analysts acknowledge potential pressure on IQOS in 2026 and see this as a risk to near term volume and earnings trajectories, even if they view the impact as temporary.
  • Some commentary includes trimmed earnings estimates for 2026 due to forex headwinds, which could cap near term upside to valuation multiples if currency pressure persists.
  • Even where targets are raised, not all firms are outright bullish. At least one maintains a Neutral stance, which signals uncertainty around how fully current reduced risk ambitions are reflected in the stock price.
  • A few analysts point out that higher expectations for reduced risk products and US pouch performance raise the bar for execution from Philip Morris International, so any missteps could challenge the higher price targets now in place.

What’s in the News for Philip Morris International

  • Philip Morris International opened a new ZYN manufacturing campus in Aurora, Colorado, with planned capital expenditures of about US$1.2b from 2024 to 2028, expanding U.S. production capacity and creating an integrated hub for domestic distribution and exports. Source, company announcement.
  • The U.S. Food and Drug Administration authorized ZYN nicotine pouches to be marketed as modified risk tobacco products, the first nicotine pouch brand to receive this designation. The FDA determined that switching completely from cigarettes to ZYN reduces exposure to harmful chemicals and is expected to lower the risk of several smoking related diseases. Source, company announcement.
  • The FDA issued Modified Risk Tobacco Product orders for 20 ZYN variants, allowing Philip Morris International to market the claim that using ZYN instead of cigarettes puts users at a lower risk of specific smoking related diseases. These are the first MRTP orders for nicotine pouches in the U.S. Source, company announcement.
  • Philip Morris International is a defendant in an ongoing lawsuit in Brazil that seeks to hold cigarette manufacturers financially accountable for public health costs attributed to smoking. All legal submissions are complete and the case is awaiting a decision from the Federal Court in Porto Alegre. Source, company announcement.
  • Recent coverage highlights that tobacco companies, including Philip Morris International, are focusing on nicotine pouches such as ZYN as a key growth area, with the category expanding in the U.S., Scandinavia, Britain, and Poland, while facing rising regulatory scrutiny and cultural barriers. Source, recent press reports.

Valuation Changes for Philip Morris International

  • Fair Value has risen slightly from $193.14 to $203.80, reflecting a modestly higher implied valuation range for Philip Morris International.
  • Discount Rate is up slightly from 7.98% to 8.05%, which points to a marginally higher required return in the updated framework.
  • Revenue Growth has edged lower from 6.12% to 5.36%, indicating slightly more conservative assumptions for future dollar sales expansion.
  • Net Profit Margin has increased marginally from 30.92% to 31.10%, suggesting a small uplift in expected profitability on each dollar of revenue.
  • Future P/E has moved higher from 24.80x to 25.98x, signalling that the updated view now applies a somewhat richer earnings multiple to Philip Morris International.
1 viewusers have viewed this narrative update

Key Takeaways

  • Accelerating global adoption of smoke-free products and regulatory support are driving strong growth, margin expansion, and lower regulatory risks for the company.
  • Investment in digital channels and geographic diversification is boosting consumer engagement, sales effectiveness, and earnings stability across emerging and established markets.
  • Declining cigarette demand, regulatory risks, illicit trade, currency volatility, and uncertain smoke-free growth jointly threaten ongoing revenue, market share, and margin stability.

Catalysts

About Philip Morris International
    Operates as a tobacco company.
What are the underlying business or industry changes driving this perspective?
  • The accelerating global adoption of smoke-free alternatives-driven by increasing health awareness and regulatory moves away from combustibles-is fueling strong double-digit volume and margin growth in PMI's IQOS, ZYN, and VEEV platforms. This secular shift enables the company to capture new consumer segments, expand its addressable market, and structurally boost net revenues and operating margins over time.
  • Growth in disposable incomes and urbanization in emerging markets is supporting robust demand expansion, particularly for PMI's smoke-free offerings, as evidenced by strong volume growth in regions such as Indonesia, Egypt, and the Middle East. Continued geographic diversification and deep market penetration are likely to provide sustained top-line growth and earnings stability.
  • PMI's increasing investment in digital channels and direct-to-consumer strategies (e.g., expanded e-commerce and data-driven marketing) is enhancing customer engagement, brand loyalty, and sales effectiveness, supporting both near
  • and long-term revenue and operating income growth.
  • Scale advantages, a broadening product portfolio, and an expanding IP moat in reduced-risk products are driving margin expansion. Smoke-free margins already surpass combustibles by over 4.5 percentage points, and as the mix continues to shift, this is expected to further increase overall net margins and free cash flow.
  • Ongoing regulatory differentiation between smoke-free and combustible products is enabling PMI to benefit from lower relative tax burdens and more favorable policy environments for its core growth portfolio, which should structurally support future earnings growth and reduce regulatory risk relative to competitors less advanced in smoke-free transformation.
Philip Morris International Earnings and Revenue Growth

Philip Morris International Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

  • Analysts are assuming Philip Morris International's revenue will grow by 5.4% annually over the next 3 years.
  • Analysts assume that profit margins will increase from 25.5% today to 31.1% in 3 years time.
  • Analysts expect earnings to reach $15.5 billion (and earnings per share of $9.96) by about August 2029, up from $10.8 billion today. The analysts are largely in agreement about this estimate.
  • In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 26.0x on those 2029 earnings, down from 27.3x today. This future PE is greater than the current PE for the GB Tobacco industry at 14.8x.
  • Analysts expect the number of shares outstanding to grow by 0.13% per year for the next 3 years.
  • To value all of this in today's terms, we will use a discount rate of 8.05%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?
  • PMI acknowledges the ongoing and potentially accelerating structural decline in combustible cigarette volumes (forecasting a return to a long-term, low single-digit decrease), driven by demographic trends, increased health consciousness, and regulatory headwinds, which may pressure total company revenue and profit as combustibles are still a sizable part of the portfolio.
  • The company highlights persistent challenges from illicit tobacco trade and counterfeit products, especially in markets like Indonesia and the EU, undercutting legal sales volumes and eroding legitimate market share, which negatively impacts revenue and operating income.
  • Regulatory and tax risks remain, particularly in the EU, where new directives may increase excise taxes on smoke-free or combustible products and where harmonized proposals could lead to greater restrictions or unfavorable changes, thus constraining both volume growth and margins for PMI's key products.
  • Currency exposure is highlighted as an ongoing risk, with volatility in major currencies (notably the Swiss franc and local emerging market currencies) impacting reported earnings, cash flow, and potentially net profit margins, as seen in recent quarterly results.
  • The company indicates the risk of a possible slowdown in smoke-free product growth (e.g., ZYN and IQOS), due either to restocking discrepancies, slower-than-expected commercial momentum, or competitive pressures, which could impact its ability to offset the secular decline in combustibles and thus threaten long-term revenue growth and operating margin expansion.

Valuation

How have all the factors above been brought together to estimate a fair value?

  • The analysts have a consensus price target of $203.8 for Philip Morris International based on their expectations of its future earnings growth, profit margins and other risk factors.
  • However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $225.0, and the most bearish reporting a price target of just $175.0.
  • In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $49.8 billion, earnings will come to $15.5 billion, and it would be trading on a PE ratio of 26.0x, assuming you use a discount rate of 8.0%.
  • Given the current share price of $189.93, the analyst price target of $203.8 is 6.8% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
  • We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Philip Morris International?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Comments

0 comments

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Read more narratives

Fair Value vs Share Price

US$203.8
vs US$188.237.6% undervalued intrinsic discount
PastFuture050b2015201820212024202620272029Revenue US$49.8bEarnings US$15.5b
5.4%
Revenue growth
31.1%
Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Philip Morris International

  • Fair value estimate changes
  • Narrative and analyst updates
  • Key company announcements

Company analysis

Solid track record established dividend payer.

Market capUS$298.5b
PB-34.2x
Estimated Growth5.1%
Dividend Yield3.1%
Full analysis

CEO & management

Jacek Olczak
CEO
3.2yrs
CEO Tenure

Operates as a tobacco company.